Company
Alterity Therapeutics Limited
ASX:ATH
Clinical-stage biotech developing disease-modifying drugs for neurodegenerative disease. Lead candidate ATH434 is an oral small molecule designed to reduce excess iron accumulation in the brain and inhibit aggregation of alpha-synuclein, the protein implicated in Multiple System Atrophy and related synucleinopathies. It targets the underlying biology of age-related neurodegeneration rather than symptoms, which is the longevity-relevant part. ATH434 has completed a randomised placebo-controlled Phase 2 trial in MSA plus an open-label Phase 2 in advanced MSA, and the company is working toward a pivotal Phase 3. It is a single-asset, pre-revenue developer, so exposure is binary on that program.
At a glance
- Listing
- ASX:ATH
- Category
- ASX listed
- Headquarters
- Melbourne, Victoria, Australia
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- ASX listed
- Market
- Australia
- Recent inflection
- 19 May 2026: Alterity presented Phase 2 ATH434 data at three meetings (ISMRM, MDSANZ, MSA Symposium at UCL), reporting a significant effect at 50 mg twice daily on functional decline (-4.0 points, p=0.035, roughly 48% slowing) and reduced swallowing decline (p=0.003 at 50 mg). The company also reported two positive Type C interactions with the US FDA and said it was on track for an End-of-Phase 2 FDA meeting around mid-2026 to enable a pivotal Phase 3.
- Services
- None recorded
- People tracked
- 1
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:ATH |
| Secondary listing | NASDAQ |
| Market cap | Not disclosed |
| Status | Listed and trading |
Get in touch
Contact
- Address
- Melbourne, Victoria, Australia
- Website
- www.globenewswire.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
People
Who variis tracks here (1)
variis does not publish portraits of named individuals without a licence to do so.
Recent inflection
What moved lately
19 May 2026: Alterity presented Phase 2 ATH434 data at three meetings (ISMRM, MDSANZ, MSA Symposium at UCL), reporting a significant effect at 50 mg twice daily on functional decline (-4.0 points, p=0.035, roughly 48% slowing) and reduced swallowing decline (p=0.003 at 50 mg). The company also reported two positive Type C interactions with the US FDA and said it was on track for an End-of-Phase 2 FDA meeting around mid-2026 to enable a pivotal Phase 3.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy · GlobeNewswire
- Alterity Therapeutics details 2026 EGM results, Form 6-K · StockTitan
- Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy · BioSpace
Every entity profile on variis is sourced. Not investment advice.